{
  "main_objectives": [
    "Extend overall survival" ],
  "treatment_administration_type": [ "IV infusion",
    "Oral Treatment (by mouth)"
  ],
  "nct_number": "NCT03371017",
  "title": "A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer",
  "first_submitted": "2017-12-07",
  "url": "https://clinicaltrials.gov/ct2/show/record/NCT03371017",
  "phases": "Phase 3",
  "enrollment": 540,
  "study_type": "Interventional",
  "control_type": "Placebo",
  "contact_name": "Reference Study ID Number: MO39193 www.roche.com/about_roche/roche_worldwide.htm",
  "conatct_phone": "888-662-6728 (U.S. and Canada)",
  "contact_email": "global-roche-genentech-trials@gene.com",
  "brief_summary": "This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).",
  "groups": [
  "Chemotherapy",
  "Immunotherapy" ],
  "countries": [ "United States"],
  "states": [
    "Georgia",
    "Tennessee",
    "Missouri",
    "Florida",
    "Pennsylvania",
    "Virginia",
    "New Jersey"],
  "cities": [
    "Marietta",
    "Nashville",
    "Kansas City",
    "Fort Myers",
    "Saint Petersburg",
    "Harrisburg",
    "Falls Church",
    "Paramus",
    "Pittsburgh"],
  "closest_facility": {
  "facility_name": "Northwest Georgia Oncology Centers PC - Marietta",
  "facility_status": "Active, not recruiting",
  "facility_country": "United States",
  "facility_state": "Georgia",
  "facility_city": "Marietta",
  "facility_zip": "30060",
  "lat": "33.948815",
  "lng": "-84.537945",
  "formatted_address": "Marietta, GA 30060, USA"
  }
}
